-
Editorial Randomized Controlled Trial Multicenter Study
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
- Gerhardt Attard, Matthew R Sydes, Malcolm D Mason, Noel W Clarke, Daniel Aebersold, Johann S de Bono, David P Dearnaley, Chris C Parker, Alastair W S Ritchie, J Martin Russell, George Thalmann, Estelle Cassoly, Robin Millman, David Matheson, Francesca Schiavone, Melissa R Spears, Mahesh K B Parmar, and Nicholas D James.
- The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
- Eur. Urol. 2014 Nov 1; 66 (5): 799-802.
AbstractThere are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..